

Support H.R. 8654 the End Tuberculosis Now Act of 2022

Please join Representatives Ami Bera (D-CA) and Maria Elvira Salazar (R-FL) in cosponsoring the bipartisan End Tuberculosis Now Act of 2022. For more information or to sign on, please contact Emma.Bruce@mail.house.gov in Representative Bera's office or JohnMark.Kolb@mail.house.gov in Representative Salazar's office.

Endorsing Organizations: American Lung Association, American Thoracic Society, America's TB Coalition, AVAC, Borgen Project, Christian Connections for International Health, Elizabeth Glaser Pediatric AIDS Foundation, Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, Georgia AIDS Coalition, Global Health Council, Global Health Technologies Coalition (GHTC), Infectious Disease Society of America, JSI, National TB Controllers Association, ONE Campaign, Partners in Health, R2H Action, RESULTS, Stop TB USA, TB Alliance, Treatment Action Group, Tuberculosis Roundtable, We Are TB

August 22, 2022

Dear Colleague:

Please join us in cosponsoring the bipartisan End Tuberculosis Now Act of 2022.

According to the World Health Organization, TB is the second leading infectious disease killer worldwide, after COVID-19, and is the leading cause of death among people living with HIV/AIDS. Drug resistant TB is the leading cause of death from drug resistance globally, including multidrug resistant (MDR) and extensively drug resistant (XDR) TB which are significantly more expensive to treat with higher rates of treatment failure. The Russian invasion of Ukraine is of particular concern, given that Ukraine has one of the highest burdens of MDR-TB in the world and is currently experiencing shortages of health supplies and care during the humanitarian crisis.

The End Tuberculosis Now Act of 2022:

- requires the U.S. to establish bold goals for reaching the most vulnerable populations to detect, cure and prevent all forms of TB globally;

- strengthens U.S. bilateral coordination with global organizations, including the Global Fund to Fight AIDS, TB, and Malaria, to develop and implement a comprehensive global TB response;
- catalyzes support for research and development (R&D) of new tools to prevent, diagnose, treat, and control TB, including drug-resistant strains of TB worldwide;
- improves the capacity of countries and affected communities with high burdens of TB to implement programs to prevent and control the spread of TB;
- requires annual reporting to Congress on U.S. TB activities and their impact, including progress in recovering from the negative effects of COVID-19 on TB; and
- evaluates the performance and the focus on impact of TB programs that are supported by U.S. bilateral assistance funding.

Many believe TB is a disease of the past, but it is still a real public health threat due to a lack of resources to properly identify, treat and prevent all forms of the disease and develop new, more effective tools to fight TB. *TB anywhere is TB everywhere* and this coordinated and comprehensive approach for supporting global TB challenges is needed to address the TB pandemic.

If you have questions or would like to sign on, please contact Emma Bruce at Emma.Bruce@mail.house.gov (Bera) or John-Mark Kolb at JohnMark.Kolb@mail.house.gov (Salazar).

Sincerely,

Ami Bera, M.D.

Member of Congress

Maria Elvira Salazar

Member of Congress